Real‐world experience of off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20407
Abstract: Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by… read more here.
Keywords: real world; lentigo maligna; experience label; label use ... See more keywords